Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses TXG in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TXG in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Serge Saxonov | $674,250 | $0 | $5,020,269 | $0 | $634,725 | $0 | $0 | $6,329,244 |
| Chief Executive Officer | ||||||||
| Eric Whitaker | 518,654 | 0 | 2,629,967 | 0 | 292,950 | 0 | 0 | 3,441,571 |
| Former Chief Legal Officer | ||||||||
| Benjamin Hindson | 518,654 | 0 | 1,793,155 | 0 | 292,950 | 0 | 0 | 2,604,759 |
| President and Chief Scientific Officer | ||||||||
| Adam Taich | 507,461 | 0 | 1,441,065 | 0 | 284,580 | 0 | 0 | 2,233,107 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Serge Saxonov | $6,329,244 | $7,929,349 | $8,286,049 | −1,600,105 |
| Eric Whitaker | 3,441,571 | 6,995,622 | 3,878,802 | −3,554,051 |
| Benjamin Hindson | 2,604,759 | 4,270,066 | 4,425,630 | −1,665,307 |
| Adam Taich | 2,233,107 | 3,296,235 | — | −1,063,128 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Adam Taich | Chief Financial Officer | 2026-05-22 | D | 15,098 | $24 | $369,018 | Common | Form 4 ↗ |
| Serge Saxonov | Director | 2026-05-22 | D | 10,718 | 25 | 264,833 | Common, open-market sale | Form 4 ↗ |
| Benjamin J. Hindson | Director | 2026-05-22 | D | 11,595 | 24 | 283,399 | Common | Form 4 ↗ |
| Serge Saxonov | Director | 2026-05-22 | D | 18,175 | 24 | 444,224 | Common | Form 4 ↗ |
| Alan Mateo | Director | 2026-06-04 | A | 8,829 | 0 | 0 | Common | Form 4 ↗ |
| Sri Kosaraju | Director | 2026-06-04 | A | 8,829 | 0 | 0 | Common | Form 4 ↗ |
| Kimberly J. Popovits | Director | 2026-06-04 | A | 8,829 | 0 | 0 | Common | Form 4 ↗ |
| John R. Stuelpnagel | Director | 2026-06-04 | A | 8,829 | 0 | 0 | Common | Form 4 ↗ |
| Shehnaaz Suliman | Director | 2026-06-04 | A | 8,829 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Teichmann | Director | 2026-06-04 | A | 8,829 | 0 | 0 | Common | Form 4 ↗ |
| Shehnaaz Suliman | Director | 2026-06-16 | D | 364 | 33 | 12,112 | Common, open-market sale | Form 4 ↗ |
| Shehnaaz Suliman | Director | 2026-06-16 | D | 5,359 | 33 | 174,644 | Common, open-market sale | Form 4 ↗ |
| Serge Saxonov | Director | 2026-06-22 | D | 9,821 | 35 | 346,837 | Common, open-market sale | Form 4 ↗ |
| Serge Saxonov | Director | 2026-06-22 | D | 9,991 | 34 | 342,506 | Common, open-market sale | Form 4 ↗ |
| Serge Saxonov | Director | 2026-06-22 | D | 1,661 | 36 | 60,069 | Common, open-market sale | Form 4 ↗ |
| Serge Saxonov | Director | 2026-06-22 | D | 8,527 | 33 | 283,855 | Common, open-market sale | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Eric Whitaker | PSU | 2025-03-17 | 7,366 | 29,464 | — | 51,562 | $317,033 |
| Serge Saxonov | PSU | 2025-03-17 | 32,142 | 128,571 | — | 224,999 | 1,383,424 |
| Adam Taich | RSU | 2025-03-17 | — | — | 133,928 | — | 1,441,065 |
| Benjamin Hindson | RSU | 2025-03-17 | — | — | 120,535 | — | 1,296,957 |
| Eric Whitaker | RSU | 2025-03-17 | — | — | 176,785 | — | 1,902,207 |
| Benjamin Hindson | PSU | 2025-03-17 | 10,044 | 20,089 | — | 40,178 | 280,041 |
| Benjamin Hindson | PSU | 2025-03-17 | 5,022 | 20,089 | — | 35,155 | 216,158 |
| Serge Saxonov | PSU | 2025-03-17 | 64,285 | 128,571 | — | 257,142 | 1,792,280 |
| Eric Whitaker | PSU | 2025-03-17 | 14,732 | 29,464 | — | 58,928 | 410,728 |
| Serge Saxonov | RSU | 2025-03-17 | — | — | 171,428 | — | 1,844,565 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Eric Whitaker | $1,902,207 | $727,761 | $0 | 27.7% |
| Serge Saxonov | 1,844,565 | 3,175,704 | 0 | 63.3% |
| Adam Taich | 1,441,065 | 0 | 0 | 0.0% |
| Benjamin Hindson | 1,296,957 | 496,199 | 0 | 27.7% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Serge Saxonov | RSU | 128,571 | — | $2,096,993 |
| Eric Whitaker | RSU | 2,670 | — | 43,548 |
| Serge Saxonov | RSU | 3,671 | — | 59,874 |
| Serge Saxonov | RSU | 213,112 | — | 3,475,857 |
| Adam Taich | RSU | 138,672 | — | 2,261,740 |
| Eric Whitaker | RSU | 132,589 | — | 2,162,527 |
| Benjamin Hindson | RSU | 39,985 | — | 652,155 |
| Eric Whitaker | RSU | 15,595 | — | 254,354 |
| Benjamin Hindson | RSU | 11,847 | — | 193,225 |
| Serge Saxonov | RSU | 49,981 | — | 815,190 |
| Eric Whitaker | RSU | 20,732 | — | 338,139 |
| Eric Whitaker | RSU | 9,747 | — | 158,974 |
| Serge Saxonov | RSU | 11,371 | — | 185,461 |
| Eric Whitaker | RSU | 69,973 | — | 1,141,260 |
| Eric Whitaker | RSU | 5,709 | — | 93,114 |
| Benjamin Hindson | RSU | 1,780 | — | 29,032 |
| Benjamin Hindson | RSU | 18,194 | — | 296,744 |
| Serge Saxonov | RSU | 44,427 | — | 724,604 |
| Benjamin Hindson | RSU | 11,371 | — | 185,461 |
| Serge Saxonov | Option | 12,236 | 69.56 | — |
| Benjamin Hindson | Option | 5,933 | 69.56 | — |
| Benjamin Hindson | Option | 12,686 | 33.67 | — |
| Benjamin Hindson | Option | 12,129 | 50.1 | — |
| Eric Whitaker | Option | 8,900 | 69.56 | — |
| Eric Whitaker | Option | 11,417 | 33.67 | — |
| Eric Whitaker | Option | 10,397 | 50.1 | — |
| Serge Saxonov | Option | 24,258 | 50.1 | — |
| Benjamin Hindson | RSU | 20,089 | — | 327,652 |
| Adam Taich | RSU | 22,321 | — | 364,056 |
| Adam Taich | RSU | 100,446 | — | 1,638,274 |
| Benjamin Hindson | RSU | 90,402 | — | 1,474,457 |
| Serge Saxonov | RSU | 72,773 | — | 1,186,928 |
| Benjamin Hindson | RSU | 67,655 | — | 1,103,453 |
| Eric Whitaker | RSU | 60,889 | — | 993,100 |
| Eric Whitaker | RSU | 29,464 | — | 480,558 |
We are committed to a pay for performance culture. We rely on incentives in the form of cash bonuses and equity compensation which are both designed to align the interests of our executive officers with those of our stockholders, and to motivate such executive officers to increase stockholder value by improving corporate performance.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 176,677,540 | 2,828,730 | 748,296 | 98.42% | Passed |
| 2025 | 2025-06-03 | 164,321,765 | 32,192,042 | 215,985 | 83.62% | Passed |
| 2024 | 2024-06-11 | 180,775,070 | 36,417,839 | 175,283 | 83.23% | Passed |
| 2023 | 2023-06-14 | 188,319,036 | 39,091,966 | 116,605 | 82.81% | Passed |
| 2022 | 2022-06-15 | 218,457,617 | 6,555,421 | 65,758 | 97.06% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-04 | 98.42%a |
| 2025 | 2025-06-03 | 83.62%b |
| 2024 | 2024-06-11 | 83.23%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 32 : 1 |
|---|---|
| CEO total compensation | $6,329,244 |
| Median employee compensation | $196,532 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John R. StuelpnagelIndependent · Board Chair · Audit (Chair) · Compensation · Mergers and Acquisitions | $143,511 | $139,902 | $0 | $0 | $0 | $283,413 |
| Sri KosarajuIndependent · Audit · Mergers and Acquisitions (Chair) | 83,420 | 139,902 | 0 | 0 | 1 | 223,323 |
| Kimberly J. PopovitsIndependent · Audit · Compensation (Chair) | 76,420 | 139,902 | 0 | 0 | 1 | 216,323 |
| Shehnaaz SulimanIndependent · Nominating and Corporate Governance (Chair) · Mergers and Acquisitions | 71,091 | 139,902 | 0 | 0 | 1 | 210,994 |
| Alan MateoIndependent · Audit · Compensation · Nominating and Corporate Governance | 68,371 | 139,902 | 0 | 0 | 0 | 208,273 |
| Sarah TeichmannIndependent | 58,420 | 139,902 | 0 | 0 | 1 | 198,323 |
| Serge SaxonovEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Benjamin J. HindsonEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Mathai MammenIndependent · Departed during FY | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $215,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 18,250 / 12,500 |
| Stock ownership guideline | Executives and directors are subject to stock ownership guidelines which align their interests with our stockholders. |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $501,233 |
| Equity awards (grant-date value) | $839,412 |
| All other compensation | $4 |
| Total cost of the board | $1,340,649 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies 10x Genomics, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including 10x Genomics, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | GoodRx Holdings, Inc. | 2025 | Wendy Barnes | $825,000 | $10,921,182 | $9,000,000 | $0 | $23,367,483 |
| 2 | Insulet Corporation | 2025 | Ashley McEvoy | 729,808 | 12,958,850 | 2,999,913 | 2,031,562 | 18,858,968 |
| 3 | Exact Sciences Corporation | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 4 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 5 | NovoCure Limited | 2025 | Ashley Cordova | 901,837 | 8,249,965 | 2,752,814 | 811,653 | 13,198,354 |
| 6 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 7 | iRhythm Technologies, Inc. | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 8 | Sotera Health Company | 2025 | Michael Petras | 1,130,699 | 8,022,400 | 0 | 1,484,890 | 10,656,063 |
| 9 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 10 | Maravai Lifesciences Holdings, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 11 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 12 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 13 | Bio-Techne Corp. | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 14 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 15 | Certara, Inc. | 2025 | William Feehery | 795,675 | 4,927,502 | 0 | 747,935 | 6,491,387 |
| 16 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 17 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 18 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 19 | Inari Medical, Inc. | 2023 | Andrew Hykes | 700,000 | 2,606,744 | 937,488 | 826,000 | 5,083,365 |
| 20 | Penumbra, Inc. | 2025 | Adam Elsesser | 850,000 | 0 | 0 | 0 | 851,621 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Azenta, Inc. | 107.4% | PSU 50 · RSU 50 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| Bio-Techne Corp. | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon Talent |
| Certara, Inc. | 94% | PSU 60 · RSU 40 | Yes — annualized total stockholder return (ATSR) | Meridian Compensation Partners |
| Exact Sciences Corporation | 47% | PSU 60 · RSU 40 | No | Aon |
| GoodRx Holdings, Inc. | 60.46% | RSU 50 · Options 50 | not disclosed | Pay Governance |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Inari Medical, Inc. | 118% | RSU 75 · Options 25 | not disclosed | FW Cook |
| Insulet Corporation | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| iRhythm Technologies, Inc. | 173% | PSU 50 · RSU 50 | No | Aon (January 1 to May 28) and Mercer (May 29 forward) |
| Maravai Lifesciences Holdings, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| NovoCure Limited | 100% | PSU 50 · RSU 25 · Options 25 | No | Frederic W. Cook & Co., Inc. |
| Penumbra, Inc. | not disclosed | not disclosed | No | Compensia |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Sotera Health Company | 103% | PSU 40 · RSU 40 · Other 20 | No | Exequity |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Serge Saxonov | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Summary Compensation Table”. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 2 | Section 01, Eric Whitaker | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Summary Compensation Table”. As printed: 3,441,571. Filing ↗machine: r11 · c48 · span 611092–611101 |
| 3 | Section 01, Benjamin Hindson | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Summary Compensation Table”. As printed: 2,604,759. Filing ↗machine: r8 · c48 · span 600571–600580 |
| 4 | Section 01, Adam Taich | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Summary Compensation Table”. As printed: 2,233,107. Filing ↗machine: r6 · c48 · span 593563–593572 |
| 5 | Section 03, Eric Whitaker PSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r18 · c19 · span 683666–683673 |
| 6 | Section 03, Serge Saxonov PSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r6 · c19 · span 641678–641687 |
| 7 | Section 03, Adam Taich RSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r9 · c19 · span 652134–652143 |
| 8 | Section 03, Benjamin Hindson RSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r13 · c19 · span 666041–666050 |
| 9 | Section 03, Eric Whitaker RSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r17 · c19 · span 680045–680054 |
| 10 | Section 03, Benjamin Hindson PSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r15 · c19 · span 673060–673067 |
| 11 | Section 03, Benjamin Hindson PSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r14 · c19 · span 669551–669558 |
| 12 | Section 03, Serge Saxonov PSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r7 · c19 · span 645191–645200 |
| 13 | Section 03, Eric Whitaker PSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r19 · c19 · span 687815–687822 |
| 14 | Section 03, Serge Saxonov RSU | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t106 · r5 · c19 · span 638165–638174 |
| 15 | Section 07, pay ratio | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “CEO Pay Ratio”. As printed: 32 : 1. Filing ↗machine: span 1030163–1030165 |
| 16 | Section 08, John R. Stuelpnagel | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Director Compensation”. As printed: 283,413. Filing ↗machine: t39 · r3 · c7 · span 255516–255523 |
| 17 | Section 08, Sri Kosaraju | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Director Compensation”. As printed: 223,323. Filing ↗machine: t39 · r4 · c7 · span 256793–256800 |
| 18 | Section 08, Kimberly J. Popovits | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Director Compensation”. As printed: 216,323. Filing ↗machine: t39 · r6 · c7 · span 259415–259422 |
| 19 | Section 08, Shehnaaz Suliman | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Director Compensation”. As printed: 210,994. Filing ↗machine: t39 · r7 · c7 · span 260727–260734 |
| 20 | Section 08, Alan Mateo | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Director Compensation”. As printed: 208,273. Filing ↗machine: t39 · r5 · c7 · span 258099–258106 |
| 21 | Section 08, Sarah Teichmann | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Director Compensation”. As printed: 198,323. Filing ↗machine: t39 · r8 · c7 · span 262294–262301 |
| 22 | Section 08, Serge Saxonov | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 08, Benjamin J. Hindson | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 24 | Section 08, Mathai Mammen | DEF 14A | 2026-04-24 | 0001628280-26-027201 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 02, Adam Taich 2026-05-22 | Form 4 | 2026-05-27 | 0001610717-26-000162 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Serge Saxonov 2026-05-22 | Form 4 | 2026-05-27 | 0001610717-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Benjamin J. Hindson 2026-05-22 | Form 4 | 2026-05-27 | 0001610717-26-000163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Serge Saxonov 2026-05-22 | Form 4 | 2026-05-27 | 0001610717-26-000164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Alan Mateo 2026-06-04 | Form 4 | 2026-06-08 | 0001610717-26-000192 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Sri Kosaraju 2026-06-04 | Form 4 | 2026-06-08 | 0001610717-26-000191 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Kimberly J. Popovits 2026-06-04 | Form 4 | 2026-06-08 | 0001610717-26-000193 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, John R. Stuelpnagel 2026-06-04 | Form 4 | 2026-06-08 | 0001610717-26-000194 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Shehnaaz Suliman 2026-06-04 | Form 4 | 2026-06-08 | 0001610717-26-000195 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Sarah Teichmann 2026-06-04 | Form 4 | 2026-06-08 | 0001610717-26-000196 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Shehnaaz Suliman 2026-06-16 | Form 4 | 2026-06-18 | 0001610717-26-000242 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Shehnaaz Suliman 2026-06-16 | Form 4 | 2026-06-18 | 0001610717-26-000242 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Serge Saxonov 2026-06-22 | Form 4 | 2026-06-24 | 0001610717-26-000293 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Serge Saxonov 2026-06-22 | Form 4 | 2026-06-24 | 0001610717-26-000293 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Serge Saxonov 2026-06-22 | Form 4 | 2026-06-24 | 0001610717-26-000293 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Serge Saxonov 2026-06-22 | Form 4 | 2026-06-24 | 0001610717-26-000293 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 06, 2026 vote | Form 8-K | 2026-06-08 | 0001628280-26-041651 | Item 5.07 · say-on-pay result. As reported: 98.42% (votes for as printed: 176,677,540). Filing ↗ |
| 42 | Section 06, 2025 vote | Form 8-K | 2025-06-05 | 0001770787-25-000040 | Item 5.07 · say-on-pay result. As reported: 83.62% (votes for as printed: 164,321,765). Filing ↗ |
| 43 | Section 06, 2024 vote | Form 8-K | 2024-06-13 | 0001770787-24-000040 | Item 5.07 · say-on-pay result. As reported: 83.23% (votes for as printed: 180,775,070). Filing ↗ |
| 44 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 45 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 46 | Section 09b board cost (computed) | Computed | — | computed | Cash 501,233 + equity 839,412 + all other 4 = 1,340,649, summed across the director compensation table rows.machine: formula: Σ = 1,340,649 |
| 47 | GoodRx Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001809519-26-000091 | CEO total compensation as printed in GoodRx Holdings, Inc.'s own proxy. As printed: 23,367,483. Filing ↗machine: t109 · r2 · c16 · span 1286734–1286744 |
| 48 | Insulet Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013333 | CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. Filing ↗machine: t218 · r3 · c25 · span 1028076–1028087 |
| 49 | Exact Sciences Corporation, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 50 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 51 | NovoCure Limited, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001645113-26-000033 | CEO total compensation as printed in NovoCure Limited's own proxy. As printed: 13,198,354. Filing ↗machine: r6 · c48 · span 880842–880852 |
| 52 | Haemonetics Corporation, Section 10b CEO total | DEF 14A | 2026-06-09 | 0000313143-26-000074 | CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183 |
| 53 | iRhythm Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001388658-26-000030 | CEO total compensation as printed in iRhythm Technologies, Inc.'s own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508 |
| 54 | Sotera Health Company, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001104659-26-040937 | CEO total compensation as printed in Sotera Health Company's own proxy. As printed: 10,656,063. Filing ↗machine: span 996859–996869 |
| 55 | Azenta, Inc., Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046064 | CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 56 | Maravai Lifesciences Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai Lifesciences Holdings, Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 57 | NeoGenomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001077183-26-000014 | CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 58 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 59 | Bio-Techne Corp., Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corp.'s own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 60 | Veracyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001384101-26-000021 | CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422 |
| 61 | Certara, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039372 | CEO total compensation as printed in Certara, Inc.'s own proxy. As printed: 6,491,387. Filing ↗machine: r1 · c42 · span 883232–883241 |
| 62 | 10x Genomics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 63 | Repligen Corporation, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 64 | Myriad Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0000899923-26-000031 | CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792987–792997 |
| 65 | Inari Medical, Inc., Section 10b CEO total | DEF 14A | 2024-03-13 | 0001193125-24-066805 | CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517 |
| 66 | Penumbra, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001321732-26-000010 | CEO total compensation as printed in Penumbra, Inc.'s own proxy. As printed: 851,621. Filing ↗machine: span 424797–424804 |
| 67 | Section 10a, iRhythm Technologies, Inc. reciprocity | DEF 14A | — | 0001388658-26-000030 | iRhythm Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |
| 68 | Section 10a, NeoGenomics, Inc. reciprocity | DEF 14A | — | 0001077183-26-000014 | NeoGenomics, Inc. names 10x Genomics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 69 | Section 10a, NovoCure Limited reciprocity | DEF 14A | — | 0001645113-26-000033 | NovoCure Limited names 10x Genomics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 70 | Section 10a, Haemonetics Corporation reciprocity | DEF 14A | — | 0000313143-26-000074 | Haemonetics Corporation's most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |
| 71 | Section 10a, Inari Medical, Inc. reciprocity | DEF 14A | — | 0001193125-24-066805 | Inari Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |
| 72 | Section 10a, Certara, Inc. reciprocity | DEF 14A | — | 0001104659-26-039372 | Certara, Inc.'s most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |
| 73 | Section 10a, Repligen Corporation reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen Corporation names 10x Genomics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 74 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc.'s most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |
| 75 | Section 10a, Sotera Health Company reciprocity | DEF 14A | — | 0001104659-26-040937 | Sotera Health Company's most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |
| 76 | Section 10a, Bio-Techne Corp. reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corp.'s most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |
| 77 | Section 10a, GoodRx Holdings, Inc. reciprocity | DEF 14A | — | 0001809519-26-000091 | GoodRx Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |
| 78 | Section 10a, Azenta, Inc. reciprocity | DEF 14A | — | 0001140361-25-046064 | Azenta, Inc. names 10x Genomics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 79 | Section 10a, Veracyte, Inc. reciprocity | DEF 14A | — | 0001384101-26-000021 | Veracyte, Inc. names 10x Genomics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 80 | Section 10a, Exact Sciences Corporation reciprocity | DEF 14A | — | 0001124140-25-000034 | Exact Sciences Corporation names 10x Genomics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 81 | Section 10a, Maravai Lifesciences Holdings, Inc. reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai Lifesciences Holdings, Inc. names 10x Genomics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, Penumbra, Inc. reciprocity | DEF 14A | — | 0001321732-26-000010 | Penumbra, Inc. names 10x Genomics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 83 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc.'s most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |
| 84 | Section 10a, Insulet Corporation reciprocity | DEF 14A | — | 0001140361-26-013333 | Insulet Corporation's most recent proxy was read; its disclosed peer group does not include 10x Genomics, Inc.. Filing ↗ |